annual EBITDA:
-$448.08M-$55.99M(-14.28%)Summary
- As of today (July 3, 2025), PCVX annual EBITDA is -$448.08 million, with the most recent change of -$55.99 million (-14.28%) on December 31, 2024.
- During the last 3 years, PCVX annual EBITDA has fallen by -$351.47 million (-363.79%).
- PCVX annual EBITDA is now -1479.25% below its all-time high of -$28.37 million, reached on December 31, 2018.
Performance
PCVX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$175.92M-$123.34M(-234.59%)Summary
- As of today (July 3, 2025), PCVX quarterly EBITDA is -$175.92 million, with the most recent change of -$123.34 million (-234.59%) on March 31, 2025.
- Over the past year, PCVX quarterly EBITDA has dropped by -$64.54 million (-57.94%).
- PCVX quarterly EBITDA is now -1599.37% below its all-time high of -$10.35 million, reached on June 30, 2019.
Performance
PCVX quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$512.75M-$64.54M(-14.40%)Summary
- As of today (July 3, 2025), PCVX TTM EBITDA is -$512.75 million, with the most recent change of -$64.54 million (-14.40%) on March 31, 2025.
- Over the past year, PCVX TTM EBITDA has dropped by -$77.47 million (-17.80%).
- PCVX TTM EBITDA is now -3736.77% below its all-time high of -$13.36 million, reached on March 31, 2019.
Performance
PCVX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
PCVX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -14.3% | -57.9% | -17.8% |
| 3 y3 years | -363.8% | -379.4% | -355.3% |
| 5 y5 years | -814.4% | -557.6% | -612.1% |
PCVX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -363.8% | at low | -279.5% | at low | -276.6% | +3.0% |
| 5 y | 5-year | -814.4% | at low | -781.1% | at low | -612.1% | +3.0% |
| alltime | all time | -1479.3% | at low | -1599.4% | at low | -3736.8% | +3.0% |
PCVX EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$175.92M(+234.6%) | -$512.75M(+14.4%) |
| Dec 2024 | -$448.08M(+14.3%) | -$52.58M(-61.1%) | -$448.21M(-15.2%) |
| Sep 2024 | - | -$135.14M(-9.4%) | -$528.34M(+5.2%) |
| Jun 2024 | - | -$149.11M(+33.9%) | -$502.11M(+15.4%) |
| Mar 2024 | - | -$111.38M(-16.1%) | -$435.28M(+11.0%) |
| Dec 2023 | -$392.10M(+83.2%) | -$132.71M(+21.9%) | -$392.10M(+17.1%) |
| Sep 2023 | - | -$108.91M(+32.4%) | -$334.88M(+18.9%) |
| Jun 2023 | - | -$82.28M(+20.7%) | -$281.53M(+14.6%) |
| Mar 2023 | - | -$68.20M(-9.7%) | -$245.61M(+14.7%) |
| Dec 2022 | -$214.03M(+121.5%) | -$75.49M(+35.9%) | -$214.10M(+29.0%) |
| Sep 2022 | - | -$55.56M(+19.9%) | -$165.97M(+21.9%) |
| Jun 2022 | - | -$46.36M(+26.3%) | -$136.16M(+20.9%) |
| Mar 2022 | - | -$36.69M(+34.1%) | -$112.61M(+14.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2021 | -$96.61M(+10.0%) | -$27.36M(+6.2%) | -$98.54M(+7.6%) |
| Sep 2021 | - | -$25.76M(+13.0%) | -$91.58M(+5.9%) |
| Jun 2021 | - | -$22.80M(+0.8%) | -$86.51M(+3.4%) |
| Mar 2021 | - | -$22.62M(+10.8%) | -$83.67M(-4.7%) |
| Dec 2020 | -$87.81M(+79.2%) | -$20.41M(-1.3%) | -$87.81M(+7.5%) |
| Sep 2020 | - | -$20.68M(+3.6%) | -$81.68M(+13.4%) |
| Jun 2020 | - | -$19.96M(-25.4%) | -$72.00M(+15.4%) |
| Mar 2020 | - | -$26.75M(+87.3%) | -$62.39M(+27.3%) |
| Dec 2019 | -$49.00M(+72.7%) | -$14.28M(+29.8%) | -$49.00M(+41.1%) |
| Sep 2019 | - | -$11.00M(+6.3%) | -$34.72M(+46.4%) |
| Jun 2019 | - | -$10.35M(-22.5%) | -$23.72M(+77.5%) |
| Mar 2019 | - | -$13.36M | -$13.36M |
| Dec 2018 | -$28.37M | - | - |
FAQ
- What is Vaxcyte annual EBITDA?
- What is the all time high annual EBITDA for Vaxcyte?
- What is Vaxcyte annual EBITDA year-on-year change?
- What is Vaxcyte quarterly EBITDA?
- What is the all time high quarterly EBITDA for Vaxcyte?
- What is Vaxcyte quarterly EBITDA year-on-year change?
- What is Vaxcyte TTM EBITDA?
- What is the all time high TTM EBITDA for Vaxcyte?
- What is Vaxcyte TTM EBITDA year-on-year change?
What is Vaxcyte annual EBITDA?
The current annual EBITDA of PCVX is -$448.08M
What is the all time high annual EBITDA for Vaxcyte?
Vaxcyte all-time high annual EBITDA is -$28.37M
What is Vaxcyte annual EBITDA year-on-year change?
Over the past year, PCVX annual EBITDA has changed by -$55.99M (-14.28%)
What is Vaxcyte quarterly EBITDA?
The current quarterly EBITDA of PCVX is -$175.92M
What is the all time high quarterly EBITDA for Vaxcyte?
Vaxcyte all-time high quarterly EBITDA is -$10.35M
What is Vaxcyte quarterly EBITDA year-on-year change?
Over the past year, PCVX quarterly EBITDA has changed by -$64.54M (-57.94%)
What is Vaxcyte TTM EBITDA?
The current TTM EBITDA of PCVX is -$512.75M
What is the all time high TTM EBITDA for Vaxcyte?
Vaxcyte all-time high TTM EBITDA is -$13.36M
What is Vaxcyte TTM EBITDA year-on-year change?
Over the past year, PCVX TTM EBITDA has changed by -$77.47M (-17.80%)